Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | CCR8 | P51685 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22121824 | 0.74 | KDM4E (0.31) | KDM4ETDP1LMNATP53HSP90AA1 | |
| SCHEMBL2409957 | 0.74 | CCR1 (0.37) | KDM4ETDP1LMNAMAPTTP53 | |
| SCHEMBL3931795 | 0.73 | — | — | |
| SCHEMBL22121613 | 0.72 | KDM4E (0.55) | KDM4ETDP1LMNAMAPTTP53 | |
| SCHEMBL8727 | 0.71 | ALDH1A1 (0.41) | KDM4EMAPTCYP3A4ALDH1A1KMT2A | |
| SCHEMBL198852 | 0.71 | KDM4E (0.32) | KDM4ETDP1LMNAMAPTTP53 | |
| SCHEMBL4854883 | 0.71 | RAB9A (0.34) | TP53CCR1CCR5SMN1; SMN2KMT2A | |
| SCHEMBL286319 | 0.71 | NUDT1 (0.33) | NUDT1 | |
| SCHEMBL3896844 | 0.70 | NR4A2 (0.43) | KDM4ETDP1LMNAMAPTTP53 | |
| SCHEMBL6163578 | 0.70 | LMNA (0.41) | KDM4ETDP1LMNAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116836193-A | Organic compound, application thereof and organic electroluminescent device comprising same | 清华大学 | 2023-10-03 | — | — | CN | claimed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-114787160-A | Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors | 因赛特公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | claimed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | claimed |
| EP-3898627-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | Incyte Corporation (US) | 2021-10-27 | — | — | EP | claimed |
| WO-2020132197-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | INCYTE CORPORATION (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200199131-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-25 | — | — | US | claimed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | claimed |
| US-5559119-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-5541192-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-5541191-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-5532355-A | IMMUNOSUPPRESSANTS FOR ORGAN TRANSPLANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-02 | — | — | US | claimed |
| US-5519031-A | TREATMENT OF RESTENOSIS, IMMUNOSUPPRESIVE AGENTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES OR ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-21 | — | — | US | claimed |
| US-5508286-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| US-5463048-A | Immunosuppressive, antiinflammatory, antifungal, antitumor, antiproliferative agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-10-31 | — | — | US | claimed |
| US-5385908-A | Hindered esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| US-5385909-A | Heterocyclic esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| US-5215997-A | Synthesis of beta-lactam compounds | CIBA-GEIGY CORPORATION (US) | 1993-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PTP4A1, PPP5C | NUDT1 1131/4885KDM4E 1572/4885TDP1 257/4885 |
| US-20200199131-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | ALK, ABL2, ACVR2A | NUDT1 525/4885KDM4E 1495/4885TDP1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.